ANIXA BIOSCIENCES INC

ANIX Healthcare Biotechnology

ANIXA BIOSCIENCES INC’s revenue for fiscal 2023 (year ended October 2023) was $210,000.00.

EPS
−14.3%
Free cash flow
−17.1%

Quarter to July 2026, against a year earlier

3.16 0.13 +4.29%
Market cap
$105.3M
P/E
0.0×
Fwd P/E
−6.0×
Dividend yield
—
F-score
n/a
Altman Z
14.47
Beneish M
n/a
Dividend safety
n/a
Older periods Oct '25 Jan '26 Apr '26 Jul '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
8.08 12.18 9.79 8.55
Net Debt/EBITDA
5.20 5.34 5.24 5.06
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.04) (0.08) (0.05) (0.05)
Book value per Share
0.43 0.42 0.39 0.39
Free Cash Flow
(1.25) (2.61) (1.74) (1.77)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 25 Oct 2026